Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.56), $0.51 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.38 million versus the consensus estimate of $5.54 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Jefferies says restaurant traffic weakened in May
• MIND Technology (MIND) Misses Q1 EPS by 5c